LeMaitre Vascular (LMAT) Set to Announce Quarterly Earnings on Thursday

LeMaitre Vascular (NASDAQ:LMAT) is set to post its quarterly earnings results after the market closes on Thursday, May 2nd. Analysts expect LeMaitre Vascular to post earnings of $0.39 per share for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Tuesday, February 27th. The medical instruments supplier reported $0.38 EPS for the quarter, topping analysts’ consensus estimates of $0.36 by $0.02. LeMaitre Vascular had a return on equity of 10.57% and a net margin of 15.56%. The firm had revenue of $48.90 million during the quarter, compared to the consensus estimate of $49.01 million. During the same quarter in the previous year, the company posted $0.25 earnings per share. The company’s revenue was up 19.3% compared to the same quarter last year. On average, analysts expect LeMaitre Vascular to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

LeMaitre Vascular Trading Down 0.3 %

Shares of NASDAQ:LMAT opened at $64.03 on Thursday. LeMaitre Vascular has a twelve month low of $44.27 and a twelve month high of $74.64. The company has a market cap of $1.44 billion, a PE ratio of 47.78, a price-to-earnings-growth ratio of 2.70 and a beta of 0.87. The company’s 50 day moving average is $65.28 and its 200 day moving average is $58.01.

LeMaitre Vascular Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 28th. Stockholders of record on Thursday, March 14th were issued a $0.16 dividend. This is an increase from LeMaitre Vascular’s previous quarterly dividend of $0.14. This represents a $0.64 annualized dividend and a dividend yield of 1.00%. The ex-dividend date was Wednesday, March 13th. LeMaitre Vascular’s dividend payout ratio is 47.76%.

Insider Buying and Selling at LeMaitre Vascular

In other news, Director John A. Roush sold 7,500 shares of the stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $69.00, for a total transaction of $517,500.00. Following the sale, the director now directly owns 2,278 shares of the company’s stock, valued at approximately $157,182. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, Director Lawrence J. Jasinski sold 5,110 shares of the stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $67.50, for a total transaction of $344,925.00. Following the transaction, the director now owns 5,309 shares in the company, valued at approximately $358,357.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director John A. Roush sold 7,500 shares of the business’s stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $69.00, for a total transaction of $517,500.00. Following the completion of the sale, the director now directly owns 2,278 shares of the company’s stock, valued at approximately $157,182. The disclosure for this sale can be found here. Over the last quarter, insiders sold 114,036 shares of company stock valued at $7,873,749. Corporate insiders own 10.79% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on LMAT. Barrington Research boosted their target price on shares of LeMaitre Vascular from $66.00 to $69.00 and gave the company an “outperform” rating in a research report on Wednesday, February 28th. StockNews.com cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Tuesday, April 16th. Finally, KeyCorp began coverage on LeMaitre Vascular in a report on Tuesday, February 6th. They set a “sector weight” rating on the stock. Three analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, LeMaitre Vascular currently has a consensus rating of “Moderate Buy” and a consensus price target of $68.20.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.